Home > News > Starpharma Holdings Limited’s VivaGel on the Fast Track to the Market
April 9th, 2007
Starpharma Holdings Limited’s VivaGel on the Fast Track to the Market
Abstract:
Starpharma Holdings Limited (ASX: SPL) makes and develops its products using nanotechnology. Its main drug is called VivaGel, a gel-based microbicide designed to protect women from sexually transmitted diseases, including HIV.
The gel has made it through Phase 1 clinical trials, and the United States Food & Drug Administration (FDA) has even granted the drug fast-track status — and fast-track designation is nothing to scoff at. The term was coined in the FDA Modernization Act of 1997 in an effort to speed up the approval process for some worthy causes. The designation is reserved for new drugs that could address unmet medical needs and treat serious or life-threatening conditions.
Source:
dailyreckoning.com.au
Bookmark:
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013